

REVENIO

Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen

Revenio Group Corporation | Stock Exchange Release | February 16, 2024 at 17:30:00 EET

Person subject to the notification requirement

Name: Robin Pulkkinen

Position: Chief Financial Officer

Issuer: Revenio Group Oyj

LEI: 743700127E0FWSXLKK04

Notification type: INITIAL NOTIFICATION

Reference number: 52730/7/6

Transaction date: 2024-02-15

Venue: NASDAQ HELSINKI LTD (XHEL)

Instrument type: SHARE

ISIN: FI0009010912

Nature of transaction: DISPOSAL

Transaction details

(1): Volume: 500 Unit price: 26 EUR

(2): Volume: 500 Unit price: 27.5 EUR

(3): Volume: 500 Unit price: 26.5 EUR

(4): Volume: 100 Unit price: 28 EUR

(5): Volume: 500 Unit price: 27 EUR

Aggregated transactions (5):

Volume: 2100 Volume weighted average price: 26.80952 EUR

For further information, please contact

CFO Robin Pulkkinen, tel. +358 50 505 9932

robin.pulkkinen@revenio.fi

Distribution

Nasdaq Helsinki

FIN-FSA

Key media

www.reveniogroup.fi

REVENIO

Revenio Group in brief

Revenio is a global provider of comprehensive eye care diagnostic solutions. The group offers fast, user-friendly, and reliable tools for diagnosing glaucoma, diabetic retinopathy, and macular degeneration (AMD). Revenio's ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand.

In 2023, the Group's net sales totaled EUR 96.6 million, with an operating profit of EUR 26.3 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

Attachments

[Revenio Group Corporation: Managers' Transactions – Robin Pulkkinen](#)